PND6 COST-EFFECTIVENESS OF GLATIRAMER ACETATE AND NATALIZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE PRESENCE OF LONG-TERM CLINICAL EVIDENCE
Abstract
Authors
JB Graham SR Earnshaw J Castelli-Haley M Oleen-Burkey KP Johnson